Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:GBT

Global Blood Therapeutics (GBT) Stock Price, News & Analysis

Global Blood Therapeutics logo

About Global Blood Therapeutics Stock (NASDAQ:GBT)

Key Stats

Today's Range
$68.49
$68.49
50-Day Range
$68.07
$68.49
52-Week Range
$21.65
$73.02
Volume
74 shs
Average Volume
2.07 million shs
Market Capitalization
$4.62 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.

Receive GBT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Global Blood Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

GBT Stock News Headlines

Elon Musk has put himself in their crosshairs
Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.
See More Headlines

GBT Stock Analysis - Frequently Asked Questions

Global Blood Therapeutics, Inc. (NASDAQ:GBT) announced its earnings results on Thursday, November, 4th. The company reported ($1.13) EPS for the quarter, missing the consensus estimate of ($1.10) by $0.03. The business's revenue for the quarter was up 41.1% compared to the same quarter last year.

Global Blood Therapeutics (GBT) raised $102 million in an initial public offering on Wednesday, August 12th 2015. The company issued 6,000,000 shares at $16.00-$18.00 per share. Morgan Stanley and Goldman Sachs acted as the underwriters for the IPO and Cowen and Company and Wedbush PacGrow were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Global Blood Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Meta Platforms (META), Intel (INTC), Bristol-Myers Squibb (BMY) and Advanced Micro Devices (AMD).

Company Calendar

Last Earnings
11/04/2021
Today
11/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:GBT
Fax
N/A
Employees
457
Year Founded
N/A

Profitability

Net Income
$-303,090,000.00
Net Margins
-137.30%
Pretax Margin
-137.01%

Debt

Sales & Book Value

Annual Sales
$194.75 million
Book Value
$3.05 per share

Miscellaneous

Free Float
64,170,000
Market Cap
$4.62 billion
Optionable
Optionable
Beta
0.45

Social Links

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

This page (NASDAQ:GBT) was last updated on 11/14/2024 by MarketBeat.com Staff
From Our Partners